IDEAYA Biosciences, Inc.(IDYA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

IDEAYA Biosciences, Inc. (IDYA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IDYA at 36.1/100 on a 32-signal composite quality model, placing it at rank #2,280 of 2,962 stocks — the bottom half of the AI-ranked universe. IDYA scores in the top quartile across revenue growth (98.2). Areas of concern include profitability (8.8) and free cash flow (9.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IDEAYA Biosciences, Inc. reports quarterly revenue of $8.9M, net income of $-112.5M, free cash flow of $-89.1M. Top institutional holders of IDYA by reported 13-F value include FMR, BlackRock, Jupiter Topco, based on the most recent SEC filings. IDYA trades on the Nasdaq exchange and files with the SEC under CIK 1676725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IDYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IDEAYA Biosciences, Inc. directly from SEC EDGAR.